Compare · GILD vs PLUR
GILD vs PLUR
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Pluri Inc. (PLUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and PLUR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $194.91B, about 14353.6x PLUR ($13.6M).
- Over the past year, GILD is up 29.6% and PLUR is down 77.7% - GILD leads by 107.3 points.
- GILD has been more active in the news (7 items in the past 4 weeks vs 5 for PLUR).
- GILD has more recent analyst coverage (25 ratings vs 0 for PLUR).
- Company
- Gilead Sciences Inc.
- Pluri Inc.
- Price
- $156.06-0.69%
- $0.87-17.92%
- Market cap
- $194.91B
- $13.6M
- 1M return
- +4.30%
- -17.92%
- 1Y return
- +29.59%
- -77.75%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 7
- 5
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
- Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
- Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
Latest PLUR
- Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company
- SEC Form 8-K filed by Pluri Inc.
- SEC Form EFFECT filed by Pluri Inc.
- Ever After Foods and Roslin Technologies Achieve Major Leap in Cultivated Meat Productivity
- SEC Form S-1 filed by Pluri Inc.
- SEC Form S-3 filed by Pluri Inc.
- SEC Form S-8 filed by Pluri Inc.
- SEC Form S-8 filed by Pluri Inc.
- SEC Form 10-K filed by Pluri Inc.
- SEC Form D filed by Pluri Inc.